Form 4: Twist Bioscience CEO Sells Shares for Tax Obligations
Insider Transaction Report
Twist Bioscience CEO Emily M. Leproust sold 2,663 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), sold 2,663 shares of common stock.
- The transaction occurred on November 21, 2025, at a price of $26.5035 per share.
- This sale was a non-discretionary "sell to cover" transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units.
- Following the transaction, Ms. Leproust directly beneficially owns 878,173 shares of common stock.
- She also holds various employee stock options, including 150,879 shares at an exercise price of $8.82, 266,539 shares at $26.66, 131,290 shares at $23.33, and 64,950 performance stock options at $67.85.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary "sell to cover" for tax purposes, which is a neutral event. It does not reflect a change in management's confidence in the company, but it also doesn't add new positive information.
Positives
- The sale was non-discretionary, solely to cover tax withholding obligations, indicating no intent to reduce personal exposure to the company's stock beyond what is legally required.
- The CEO continues to hold a substantial number of shares and stock options, aligning her interests with shareholders.
Negatives
- A reduction in direct share ownership, even if for tax purposes, slightly decreases the CEO's direct equity stake.
Future Outlook
No specific forward-looking statements or guidance are provided in this Form 4 filing.
Industry Context
This filing is a routine insider transaction report, common across all industries for publicly traded companies when executives' restricted stock units vest and shares are sold to cover tax obligations. It does not provide specific insights into broader industry trends for the biotechnology or synthetic biology sector where Twist Bioscience operates.
Comparison to Industry Standards
- This is a standard "sell to cover" transaction, a common practice for executives across publicly traded companies globally when equity awards vest. It is not comparable to specific company projects or results.
Stakeholder Impact
- Shareholders: Minimal direct impact. The sale is small relative to the CEO's total holdings and the company's market capitalization. It's a routine event for equity compensation.
- Employees: No direct impact mentioned.
- Customers: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | 25% of shares subject to employee stock option ($5.95 exercise price) vested, with 1/48th vesting monthly thereafter. |
| 09/28/2017 | 10% of shares subject to employee stock option ($8.82 exercise price) vested. |
| 09/28/2018 | 15% of shares subject to employee stock option ($8.82 exercise price) vested, with 1/48th vesting monthly thereafter. |
| 10/31/2019 | 20% of shares subject to employee stock option ($26.66 exercise price) vested, with 1/60th vesting monthly thereafter. |
| 09/01/2020 | Performance stock options ($67.85 exercise price) granted to the reporting person. |
| 10/24/2020 | 25% of shares subject to employee stock option ($23.33 exercise price) vested, with 1/48th vesting monthly thereafter. |
| 12/19/2022 | Performance stock options ($67.85 exercise price) vested and became exercisable due to meeting applicable performance criteria. |
| 09/28/2025 | Expiration date for employee stock option with $5.95 exercise price. |
| 11/21/2025 | Transaction date for the sale of 2,663 shares of common stock. |
| 11/25/2025 | Date of filing of the Statement of Changes in Beneficial Ownership. |
| 09/28/2027 | Expiration date for employee stock option with $8.82 exercise price. |
| 11/18/2028 | Expiration date for employee stock option with $26.66 exercise price. |
| 10/23/2029 | Expiration date for employee stock option with $23.33 exercise price. |
| 08/31/2030 | Expiration date for employee stock option with $67.85 exercise price. |
Recommendation
holdThis Form 4 filing details a routine, non-discretionary "sell to cover" transaction by the CEO to satisfy tax obligations upon RSU vesting. Such transactions are common and generally do not indicate a change in management's outlook or confidence in the company. The CEO retains a significant equity stake. Therefore, this specific filing provides no new information that would warrant a change in investment recommendation; a "hold" stance is appropriate, pending further fundamental analysis of the company's performance and market conditions.
Keywords
Twist Bioscience, TWST, Emily M. Leproust, Insider Trading, Form 4, Sell to Cover, Restricted Stock Units, Stock Options, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.